Cyclophosphamide IV

Phase 3Small molecule

AAssistance Publique - Hôpitaux de Paris

Cyclophosphamide IV is one of 14 small molecule programs targeting Paraneoplastic Sensory Neuronopathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Paraneoplastic Sensory NeuronopathyRecruiting

Hematopoietic Stem Cell TransplantationNot yet recruiting

Paraneoplastic Sensory NeuronopathyPhase 2

Recruiting

Hematopoietic Stem Cell TransplantationPhase 3

Not yet recruiting

Competition

Competitive Landscape

13 competitors in Hematopoietic Stem Cell Transplantation

#DrugCompanyPhaseTrials

Cyklokapron

JJ Molner

Phase 3

1 2

Fludara

Sanofi

Phase 2

4 3

Alkeran

AApotex Inc.

Phase 2

3 4

Campath

GGenzyme, a Sanofi Company

Phase 2

1 5

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 6

Cyclophosphamide IV

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 7

Interleukin 2

EEssen Biotech

Phase 1

1 8

IFN-γ Positive Selected T-Cells

UUniversity Hospital, Basel, Switzerland

Phase 2

1 9

Dose Extension

IInstitute of Hematology & Blood Diseases Hospital, China

Phase 1

1 10

Piperacillin-Tazobactam Combination Product

TThe University of Queensland

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Paraneoplastic Sensory Neuronopathy

NCT06373211

Q3 2029

Phase 3Not yet recruiting

Hematopoietic Stem Cell Transplantation

NCT07193420

Clinical

Trials by Indication[1]

Hematopoietic Stem Cell Transplantation1 trial

Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT07193420·180 enrolled

Interstitial Lung Disease1 trial

Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT03770663·76 enrolled

Multiple Myeloma1 trial

Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT01208818·284 enrolled

Paraneoplastic Sensory Neuronopathy1 trial

Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory Neuronopathy

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06373211·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Cyclophosphamide IV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cyclophosphamide IV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cyclophosphamide IV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAssistance Publique - Hôpitaux de Paris

Cyclophosphamide IV

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2029

Trials by Indication[1]

Hematopoietic Stem Cell Transplantation1 trial

Interstitial Lung Disease1 trial

Multiple Myeloma1 trial

Paraneoplastic Sensory Neuronopathy1 trial

References

Drug Info

Quick Facts

Related News